Daraxonrasib trial finds no detectable tumors in 8.2%
A small clinical trial found no detectable tumors in 8.2% of patients who received daraxonrasib with chemotherapy for advanced pancreatic cancer. Researchers reported longer-term follow-up is needed, while a cancer charity said more trials must precede an assessment of the treatment for NHS use.

Daraxonrasib combined with chemotherapy left no detectable tumors in 8.2% of patients with advanced pancreatic cancer, according to a clinical trial. The findings came from a study of 61 patients and a typical follow-up of 18 months.
The drug is a once-daily pill. Tumors shrank or disappeared in 60.7% of patients who received it with chemotherapy.
Researchers presented the phase one/two findings at the European Organisation for Research and Treatment of Cancer in Barcelona. Longer-term survival data will come as the trial progresses.
Trial measures survival and tumor growth
One year after treatment, 76.6% of patients were alive. That compares with around 40 to 45% of patients given chemotherapy alone.
Tumors stopped growing in 90.2% of the 61 patients over a typical period of 18 months. Across the group, tumors took an average of 12.8 months to return or start growing again.
Dr. Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Centre in New York, presented the findings. He called the results “a massive, massive breakthrough” in treating pancreatic cancer.
Asked whether patients whose tumors were no longer detectable were cured, Park said: “This is the closest to cure.”
Cancer frequently develops resistance to drug treatment, Park said. He said the combination aims to delay that resistance.
Daraxonrasib targets the mutated KRAS gene, which is found in more than nine in 10 pancreatic tumors. The gene continuously signals cancer cells to grow.
Earlier findings showed the drug almost doubled survival time compared with chemotherapy alone in patients with aggressive, advanced pancreatic cancer. It also caused fewer side effects.
Researchers call for more trials
Dr. Madina Kara, head of research at Pancreatic Cancer UK, called the findings encouraging while describing the study as small and initial. She said the results showed the drug and chemotherapy could be effective together.
Kara said half of people with pancreatic cancer die within three months of diagnosis. More than 11,000 people are diagnosed with the disease each year in the UK, and more than 10,000 die from it.
She called on the UK Government to increase investment in pancreatic research and clinical trials. She also sought a rapid pathway to deliver new treatments once they are proven to work.
Cancer Research UK chief executive Michelle Mitchell said more trials are needed before the treatment can be assessed for NHS use. She also called for research into how the drug could be used alongside other therapies.
The final phase-three study has enough patients in the US, although some sites in Europe may have space.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1Stock Market Today: Dow Slides 1.34% and VIX Jumps 15% at Midday

- 2Joachim Klement to Sell Stocks After S&P 500 Signal

- 3Kenneth Walker’s Groin Injury Puts Cardinals Game in Doubt

- 4Stock Market Today: Nasdaq, S&P 500 Futures Slide as AI Selloff Deepens

- 5Pat Cummins Faces Captaincy Doubts From Mitchell Johnson

Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say
Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts















